Viagra. As Pfizer had spent a heavy R&D on Viagra and to make sure the success of it preceding its competitors, it had to think of ways to outperform them and always maintaining itself in the leading position and profitability.

Authors Avatar

1.0        CASE SUMMARY

Pfizer is currently the world’s largest drug company with revenues of $32.4 billion and an R&D budget of 7.1 billion as in year 2003. It became the world’s largest pharmaceutical company, after its merger with Warner-Lambert in July 2000. It is also considered as the industry’s best marketer. The company has three business segments, they are, health care, animal health and consumer health. Pfizer’s products are found in over 150 countries.

        Pfizer is the first company which highlighted erectile dysfunction (ED) as a curable sickness and came out with their famous blue pill, Viagra. It had spent close to $2.5 billion for this pill in R&D and another $185 million annually to promote it. The marketing channel used is via medical sales representatives who promote Viagra to medical practitioners (doctors) and pharmacies.

        Viagra was considered a success in the first five years when it was introduced into the market in the 1990’s. However, later on, competitors such as Bayer/Glaxo SmithKline Beecham and Eli Lilly had also introduced their version of pills for ED. This had threatened Pfizer’s previously monopoly market.

        The case study had a detailed description on Viagra, Pfizer as well as its competitors. Challenges were also highlighted in the case and Pfizer would have to reconsider a change or modification of its marketing strategies in order to maintain as the leading company in providing solution for ED, and to recap the heavy R&D investment it had done previously.

  1. PROBLEM STATEMENT

As Pfizer had spent a heavy R&D on Viagra and to make sure the success of it preceding its competitors, it had to think of ways to outperform them and always maintaining itself in the leading position and profitability.

The following symptoms had been identified:

  • Rivals such as Bayer/Glaxo and Eli Lilly have come out with their own products and compete direct with Pfizer’s Viagra.
  • Pfizer was not able to meet its sales target with Viagra.
  • Pfizer could not get an endorsement for coverage under insurance coverage.
  • Patent issue, whereby it patent on Viagra is expiring in year 2019.

Therefore, the problem statement identified is, how should Pfizer strategize itself in marketing, in order to compete in ED via Viagra.

  1. SWOT ANALYSIS
  1. EXTERNAL FACTORS ANALYSIS SUMMARY (EFAS)

Opportunities

O1        US Market share

  • Pfizer is the pioneer of prescription for ED. Hence, it enjoys the first mover advantage.

O2        US Untapped Market

  • There are 30 million men with ED in US in year 2000. However, only 13% of them had tried Viagra. There are still 87% untapped market.

O3        Increasing Global Demand

  • ED is found to be a global problem. Men with ED in other parts of the world are also seeking treatment. This has increased the opportunity for Pfizer to distribute Viagra globally.

O4        Internet Boom

  • Taking advantage of internet boom, Pfizer shall take opportunity to market and channel Viagra through internet marketing not only to US but also to the rest of the world.

O5        Product Innovation

  • Movement to non-oral based treatment for ED.
  • Treatment for women with sexual dysfunction.

Threat

T1        Heavy Competition

  • Other pharmaceutical company follow suits by introducing their own version “Viagra”.
  • Example, Bayer/GSK with Levitra and Eli Lilly with Cialis
  • Competitor employs internet marketing, i.e. spamming

T2        Traditional Prescription

  • In contrast to Viagra which is based on drugs, there is an alternative prescription which is based of herbs, i.e. Tongkat Ali and Ginseng.
Join now!

T3        Patent Issues

  • Existing Patent protection is only limited to year 2019.
  • Generic drug manufacturers spend minimum resources on R&D. They start manufacturing only after other companies patent expired. Subsequently, they able to offer the drugs at cheaper price than the originator.

EFAS Summary

The weighted scores for Viagra of 3.55 indicate that the company is averagely responding to the external environment. On the other hand, Levitra is below average in managing its external environment.


WEIGHT JUSTIFICATION OF EFAS TABLE

Justification is only detailed for the prominent factors identified in the ...

This is a preview of the whole essay